|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026809,
umls-concept:C0038317,
umls-concept:C0087111,
umls-concept:C0162351,
umls-concept:C0205191,
umls-concept:C0332237,
umls-concept:C0457454,
umls-concept:C0771892,
umls-concept:C1444662,
umls-concept:C1522168,
umls-concept:C1882365
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-1-14
|
|
pubmed:abstractText |
Olopatadine hydrochloride (olopatadine; Allelock) is one of the second-generation antihistamines that are treated for allergic disorders such as rhinitis, urticaria and eczema dermatitis. Olopatadine has recently been shown to have inhibitory effects on the chronic contact hypersensitivity induced by repeated application of oxazolone in mice. Although topical steroids have widely been prescribed for atopic dermatitis, a relapse often occurs within several days after discontinuation of their prolonged use.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0954-7894
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-103
|
|
pubmed:meshHeading |
pubmed-meshheading:15649273-Animals,
pubmed-meshheading:15649273-Chronic Disease,
pubmed-meshheading:15649273-Dermatitis, Contact,
pubmed-meshheading:15649273-Dibenzoxepins,
pubmed-meshheading:15649273-Glucocorticoids,
pubmed-meshheading:15649273-Histamine H1 Antagonists,
pubmed-meshheading:15649273-Interleukin-4,
pubmed-meshheading:15649273-Male,
pubmed-meshheading:15649273-Mice,
pubmed-meshheading:15649273-Mice, Inbred BALB C,
pubmed-meshheading:15649273-Models, Animal,
pubmed-meshheading:15649273-Prednisolone,
pubmed-meshheading:15649273-Recurrence,
pubmed-meshheading:15649273-Substance Withdrawal Syndrome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity.
|
|
pubmed:affiliation |
Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd, Shizuoka, Japan. tadafumi.tamura@kyowa.co.jp
|
|
pubmed:publicationType |
Journal Article
|
